manufacturing update, page-22

Hmmm.....smoke and mirrors!

me thinks that is was a clear announcement with little detail on how the company is dealing with BP and the significant question of the manufacturing rights for the project which is key for a trade sale.

My understanding that the delivery system was generic is type, so I wonder why the company would have gone to Therapex if they need to undertake capital improvements on the ArTiMist™ filling equipment and filling room modifications. I am sure that the cost of this work will be build into the per unit cost.

If with all the positive expectations to come from the clinical phase III trial...I am still very surprised that no third party has entered into at least an option for the rights for the project...me asks the question why not!

Phase III was in practice just required step, but based on the type of product artimist is and the past results ...it was of a very high level of expectation that there would not have been any negative findings.

Therapex is only a replacement for the initial supply of product since the UK route fell away and note ..The agreement is a fee for service agreement and is not a Manufacturing license or a joint venture agreement.

So while we have had a nice little run, I am like a number of others looking of some level on comments from the company of the current level of dialogue re trade sale and the BP issue where nothing has been forthcoming for quite sometime???????

What do other think?